ViroGates A/S's latest marketcap:
As of 07/26/2025, ViroGates A/S's market capitalization has reached $12.84 M. According to our data, ViroGates A/S is the 39341th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 12.84 M |
| Revenue (ttm) | 1.07 M |
| Net Income (ttm) | -2,129,102.29 |
| Shares Out | 7.73 M |
| EPS (ttm) | -0.28 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/21/2025 |
ViroGates A/S's yearly market capitalization.
| Date | Market Cap(kr) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/26/2025 | kr81.6 M | $12.84 M | -0.47% | 39341 |
| 12/30/2024 | kr81.99 M | $11.34 M | 111.23% | 37373 |
| 12/29/2023 | kr38.81 M | $5.75 M | -71.09% | 39208 |
| 12/30/2022 | kr134.25 M | $19.27 M | -70.57% | 32826 |
| 12/30/2021 | kr456.12 M | $69.71 M | 79.21% | 25471 |
| 12/30/2020 | kr254.51 M | $41.66 M | 144.75% | 25754 |
| 12/30/2019 | kr103.99 M | $15.56 M | -42.83% | 27373 |
| 12/28/2018 | kr181.91 M | $27.85 M | 24007 |
Company Profile
About ViroGates A/S
ViroGates A/S is an in vitro diagnostics company specializing in the development and marketing of prognostic products for the healthcare sector.
Key Products
suPARnostic – A proprietary biomarker used in hospital emergency services to support clinical decisions regarding patient hospitalization or discharge. It also aids in early identification of high-risk sepsis patients and provides prognosis for lifestyle-related diseases such as:
- Cardiovascular disease
- Type 2 diabetes
- Cancer
Additionally, suPARnostic is used for assessing longevity and biological age in non-hospital settings.
Product Portfolio
- suPARnostic TurbiLatex – A latex particle-enhanced turbidimetric immunoassay for quantitative suPAR level determination in human plasma samples.
- suPARnostic ELISA – Provides fully quantitative results for suPAR levels.
- suPARnostic Quick Triage Kit – A point-of-care solution for early warning and patient triaging, enabling fast disease severity and progression assessment.
- suPARnostic POC+ – A finger prick test for detecting suPAR levels in blood at the point of care.
Company Background
Founded in 2000, ViroGates A/S is headquartered in Birkerød, Denmark.
Frequently Asked Questions
-
What is ViroGates A/S's (CPH-VIRO) current market cap?As of 07/26/2025, ViroGates A/S (including the parent company, if applicable) has an estimated market capitalization of $12.84 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does ViroGates A/S (CPH-VIRO) rank globally by market cap?ViroGates A/S global market capitalization ranking is approximately 39341 as of 07/26/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.